David Altshuler and the Vertex / CRISPR team have taken historic milestone in the search for a curative gene editing approach to sickle cell disease, beta thalassemia – Endpoints News



[ad_1]

Ridding the world of Covid-19 is a lucrative business.

As analysts divide the multibillion-dollar rewards for leaders in the race to roll out the first pandemic vaccines, no one forgets to follow how much the company’s main founders have at stake now as the prices go. stocks are turning higher and higher.

Bloomberg, who follows these numbers with missionary zeal, today estimates Sahin’s net worth at $ 5.1 billion following BioNTech’s most recent rise in BNTX’s dollar share price. Biotech partner Pfizer is actively pushing forward plans to implement the first approved vaccine, and Bernstein believes that will put the two collaborators in line for the biggest market share for next year.

Endpoints News

Keep Reading Endpoints With A Free Membership

Unlock this story instantly and join over 94,700 biopharmacy pros who read Endpoints daily – and it’s free.


[ad_2]

Source link